Glioblastoma (GBM) is the most common primary brain cancer and considered invariably
fatal. Despite decades of research, there have been few innovations in treatment that
have improved survival [
[1]
,
[2]
]. Gliomas and GBMs have historically been classified histologically until 2016, when
the World Health Organization (WHO) instituted an additional molecular classification
system based on isocitrate dehydrogenase (IDH) mutational status and 1p19q chromosomal
codeletion [
3
,
4
,
5
]. Around 70% percent of gliomas and 5–7% of primary GBMs harbor mutations in IDH
[
[6]
,
[7]
]. IDH-mutant tumors are thought to be more sensitive to chemotherapy and radiotherapy,
although this has yet to be translated into differences in treatment recommendations.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N. Engl. J. Med. 2005; 352: 987-996https://doi.org/10.1056/NEJMoa043330
- Effect of tumor-treating fields plus maintenance Temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial.JAMA. 2017; 318: 2306-2316https://doi.org/10.1001/jama.2017.18718
- The 2016 World Health Organization classification of tumors of the central nervous system: a summary.Acta Neuropathol. 2016; 131: 803-820https://doi.org/10.1007/s00401-016-1545-1
- Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas.N. Engl. J. Med. 2015; 372: 2481-2498https://doi.org/10.1056/NEJMoa1402121
- Misclassification of diffuse gliomas — Letter.Clin. Cancer Res. 2020; 26: 1198https://doi.org/10.1158/1078-0432.CCR-19-3257
- An integrated genomic analysis of human glioblastoma multiforme.Science. 2008; 321: 1807-1812https://doi.org/10.1126/science.1164382
- IDH1 and IDH2 mutations in gliomas.N. Engl. J. Med. 2009; 360: 765-773https://doi.org/10.1056/NEJMoa0808710
- Purine metabolism regulates DNA repair and therapy resistance in glioblastoma.Nat. Commun. 2020; 11: 3811https://doi.org/10.1038/s41467-020-17512-x
- Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese gliomas.Genom. Proteomics Bioinformatics. 2021; https://doi.org/10.1016/j.gpb.2020.10.005
- Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor.Cell. 2018; 175 (e1618): 1665-1678
- Rembrandt: helping personalized medicine become a reality through integrative translational research.Mol. Cancer Res. 2009; 7: 157https://doi.org/10.1158/1541-7786.MCR-08-0435
- Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.J. Neurosurg. 2020; : 1-11https://doi.org/10.3171/2020.2.Jns192767
- Extent of resection and survival for oligodendroglioma: a U.S. population-based study.J. Neuro-Oncol. 2019; 144: 591-601https://doi.org/10.1007/s11060-019-03261-5
Article info
Publication history
Published online: April 08, 2021
Accepted:
April 6,
2021
Received in revised form:
March 28,
2021
Received:
February 18,
2021
Identification
Copyright
© 2021 Elsevier B.V. All rights reserved.
